Advertisement

Cardiovascular Drugs and Therapy

, Volume 20, Issue 3, pp 205–217 | Cite as

The Clinical Relevance of Low-Density-Lipoproteins Size Modulation by Statins

  • Manfredi RizzoEmail author
  • Kaspar Berneis
Review Article

Abstract

The predominance of small, dense low density lipoproteins (LDL) has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III; in fact, LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart disease. Several studies have also shown that the therapeutical modulation of LDL size is of great benefit in reducing the risk of cardiovascular events. Hypolipidemic treatment is able to alter LDL subclass distribution and statins are currently the most widely used lipid-lowering agents. Statins are potent inhibitors of hydroxy-methyl-glutaryl-coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol synthesis and are the main drugs of choice for the treatment of elevated plasma LDL cholesterol concentrations. Statins potentially lower all LDL subclasses (e.g., large, medium and small particles); thus, their net effect on LDL subclasses or size is often only moderate. However, a strong variation has been noticed among the different agents: analyses of all published studies suggest a very limited role of pravastatin and simvastatin in modifying LDL size and their subclasses, while fluvastatin and atorvastatin seem to be much more effective agents. Finally, rosuvastatin, the latest statin molecule introduced in the market, seems to be promising in altering LDL subclasses towards less atherogenic particles.

Key words

statins small, dense LDL coronary heart disease atherosclerosis prevention therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Krauss RM. Dietary and genetic probes of atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol 2005;25:2265–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Packard C, Caslake M, Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol 2000;74:S17–22.PubMedCrossRefGoogle Scholar
  3. 3.
    Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002;43:1363–79.PubMedCrossRefGoogle Scholar
  4. 4.
    Georgieva AM, van Greevenbroek MMJ, Krauss RM, Brouwers MCGJ, Vermeulen VMM-J, Robertus-Teunissen MG, van der Kallen CJH, de Bruin TWA. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2004;24:1–7.CrossRefGoogle Scholar
  5. 5.
    Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size? Int J Card 2006;107:147–51.CrossRefGoogle Scholar
  6. 6.
    Rizzo M, Barbagallo CM, Severino M, Polizzi F, Onorato F, Noto D, Cefalu AB, Pace A, Marino G, Notarbartolo A, Averna RM. Low-density-lipoprotein peak particle size in a Mediterranean population. Eur J Clin Invest 2003;33:126–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495–506.PubMedGoogle Scholar
  8. 8.
    Rizzo M, Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscler Thromb 2005;12:237–9.PubMedGoogle Scholar
  9. 9.
    National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421. 23.Google Scholar
  10. 10.
    Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Sacks FM, Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocr Metab 2003;88:4525–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Berneis K, Rizzo M. LDL size: does it matter? Swiss Med Weekly 2004;134:720–4.Google Scholar
  13. 13.
    O'Keefe JH Jr, Harris WS, Nelson J, Windsor SL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol 1995;76(7):480–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002;90(2):89–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 2002;160(1):41–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Vega GL, Krauss RM, Grundy SM. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 1990;227(2):81–94.PubMedCrossRefGoogle Scholar
  17. 17.
    Cheung MC, Austin MA, Moulin P, Wolf AC, Cryer D, Knopp RH. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 1993;102(1):107–19.PubMedCrossRefGoogle Scholar
  18. 18.
    Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 1993;13(12):1755–62.PubMedGoogle Scholar
  19. 19.
    Zambon S, Cortella A, Sartore G, Baldo-Enzi G, Manzato E, Crepaldi G. Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size. Eur J Clin Pharmacol 1994;46(3):221–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Franceschini G, Cassinotti M, Vecchio G, Gianfranceschi G, Pazzucconi F, Murakami T, Sirtori M, D'Acquarica AL, Sirtori CR. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb 1994;14(10):1569–75.PubMedGoogle Scholar
  21. 21.
    Guerin M, Dolphin PJ, Talussot C, Gardette J, Berthezene F, Chapman MJ. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15(9):1359–68.PubMedGoogle Scholar
  22. 22.
    Contacos C, Barter PJ, Vrga L, Sullivan DR. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. Atherosclerosis 1998;141(1):87–98.PubMedCrossRefGoogle Scholar
  23. 23.
    Lemieux I, Laperriere L, Dzavik V, Tremblay G, Bourgeois J, Despres JP. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 2002;162(2):363–371.PubMedCrossRefGoogle Scholar
  24. 24.
    Blake GJ, Albert MA, Rifai N, Ridker PM. Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial. Eur Heart J 2003;24(20):1843–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Kazama H, Usui S, Okazaki M, Hosoi T, Ito H, Orimo H. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res Clin Pract 2003;59(3):181–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Sirtori CR, Calabresi L, Pisciotta L, Cattin L, Pauciullo P, Montagnani M, Manzato E, Bittolo Bon G, Fellin R. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. Nutr Metab Cardiovasc Dis 2005;15(1):47–55.PubMedCrossRefGoogle Scholar
  27. 27.
    Nestel P, Simons L, Barter P, Clifton P, Colquhoun D, Hamilton-Craig I, Sikaris K, Sullivan D. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 1997;129(2):231–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. J Cardiol 2003;91(8):956–60.CrossRefGoogle Scholar
  29. 29.
    Rizzo M, Barbagallo CM, Pernice V, Pace A, Noto D, Rubino A, Pinto V, Traina M, Pieri D, Frasheri A, Scimeca A, Cuffaro MP, Caldarella R, Scalisi G, Notarbartolo A, Averna MR. Effects “beyond-cholesterol” of statins: simvastatin reduces the levels of atherogenic lipoproteins in patients with premature coronary artery disease. Nutr Metab Cardiovasc Dis 2002;12(4):239.Google Scholar
  30. 30.
    Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 2002;164(1):129–45.PubMedCrossRefGoogle Scholar
  31. 31.
    Wakatsuki A, Ikenoue N, Izumiya C, Okatani Y, Sagara Y. Effect of estrogen and simvastatin on low-density lipoprotein subclasses in hypercholesterolemic postmenopausal women. Obstet Gynecol 1998;92(3):367–72.PubMedCrossRefGoogle Scholar
  32. 32.
    Wakatsuki A, Okatani Y, Ikenoue N. Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia. Atherosclerosis 2000;150(1):103–11.PubMedCrossRefGoogle Scholar
  33. 33.
    Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis 1996;7(11):843–50.PubMedGoogle Scholar
  34. 34.
    Zhao SP, Hollaar L, van 't Hooft FM, Smelt AH, Gevers Leuven JA, van der Laarse A. Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia. Clin Chim Acta 1991;16;203(2–3):109–17.CrossRefGoogle Scholar
  35. 35.
    Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Nakamura H. Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis 1995;114(2):223–34.PubMedCrossRefGoogle Scholar
  36. 36.
    Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 2003; 6(4):179–88.PubMedGoogle Scholar
  37. 37.
    Nakandakare E, Garcia RC, Rocha JC, Sperotto G, Oliveira HC, Quintao EC. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Atherosclerosis 1990;85(2–3):211–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Gaw A, Packard CJ, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, Vallance BD, Lorimer AR, Shepherd J. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb 1993;13(2):170–89.PubMedGoogle Scholar
  39. 39.
    de Graaf J, Demacker PN, Stalenhoef AF. The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia. Neth J Med 1993;43(5–6):254–61.PubMedGoogle Scholar
  40. 40.
    Bredie SJ, de Bruin TW, Demacker PN, Kastelein JJ, Stalenhoef AF. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 1995;15;75(5):348–53.CrossRefGoogle Scholar
  41. 41.
    Hoogerbrugge N, Jansen H, De Heide L, Zillikens MC, Deckers JW, Birkenhager JC. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. J Intern Med 1998;243(5):151–6.PubMedGoogle Scholar
  42. 42.
    Lagrost L, Athias A, Lemort N, Richard JL, Desrumaux C, Chatenet-Duchene L, Courtois M, Farnier M, Jacotot B, Braschi S, Gambert P. Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin. Atherosclerosis 1999 Apr;143(2):415–25.PubMedCrossRefGoogle Scholar
  43. 43.
    Nishikawa O, Mune M, Miyano M, Nishide T, Nishide I, Maeda A, Kimura K, Takahashi T, Kishino M, Tone Y, Otani H, Ogawa A, Maeda T, Yukawa S. Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney Int Suppl 1999;71:S219–21.PubMedCrossRefGoogle Scholar
  44. 44.
    Geiss HC, Schwandt P, Parhofer KG. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia. Exp Clin Endocrinol Diabetes 2002;110(4):182–7.PubMedCrossRefGoogle Scholar
  45. 45.
    van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003;16(2):238–44.PubMedGoogle Scholar
  46. 46.
    van Tits LJ, Smilde TJ, van Wissen S, de Graaf J, Kastelein JJ, Stalenhoef AF. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J Investig Med 2004; 52(3):177–84.PubMedGoogle Scholar
  47. 47.
    Yuan JN, Tsai MY, Hegland J, Hunninghake DB. Effects of fluvastatin (XU 62–320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 1991;87(2–3):147–57.PubMedCrossRefGoogle Scholar
  48. 48.
    Moriguchi EH, Vieira JL, Itakura H. Differences in the effects of fluvastatin on lipoprotein subclasses distribution is dependent on triglyceride levels. Atherosclerosis 2001;(Suppl. 2):140–1. (abstract)Google Scholar
  49. 49.
    Marz W, Scharnagl H, Abletshauser C, Hoffmann MM, Berg A, Keul J, Wieland H, Baumstark MW. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 2001;103(15):1942–8.PubMedGoogle Scholar
  50. 50.
    Yoshino G, Hirano T, Kazumi T, Takemoto M, Ohashi N. Fluvastatin increases LDL particle size and reduces oxidative stress in patients with hyperlipidemia. J Atheroscler Thromb 2003;10(6):343–7.PubMedGoogle Scholar
  51. 51.
    Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N. Fluvastatin improves endothelial dysfunction in overweight postmenopausal women through small dense low-density lipoprotein reduction. Metabolism 2004;53(6):733–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Winkler K, Abletshauser C, Hoffmann MM, Friedrich I, Baumstark MW, Wieland H, Marz W. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 2002;87(12):5485–90.PubMedCrossRefGoogle Scholar
  53. 53.
    Superko HR, Krauss RM, DiRicco C. Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol 1997;80(1):78–81.PubMedCrossRefGoogle Scholar
  54. 54.
    Hoogerbrugge N, Jansen H. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis 1999 Sep;146(1):167–74.PubMedCrossRefGoogle Scholar
  55. 55.
    Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000 Jan;20(1):189–97.PubMedGoogle Scholar
  56. 56.
    Nordoy A, Hansen JB, Brox J, Svensson B. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr Metab Cardiovasc Dis 2001 Feb;11(1):7–16.PubMedGoogle Scholar
  57. 57.
    Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, Brunzell JD; Rosiglitazone Study 108 investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002 Nov 1;90(9):947–52.PubMedCrossRefGoogle Scholar
  58. 58.
    Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002 Mar;51(3):334–42.PubMedCrossRefGoogle Scholar
  59. 59.
    Sasaki S, Kuwahara N, Kunitomo K, Harada S, Yamada T, Azuma A, Takeda K, Nakagawa M. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 2002 Feb 15;89(4):386–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y. Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients. Circ J 2003 Oct;67(10):866–70.PubMedCrossRefGoogle Scholar
  61. 61.
    Lariviere M, Lamarche B, Pirro M, Hogue JC, Bergeron J, Gagne C, Couture P. Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia. Atherosclerosis 2003 Mar;167(1):97–104.PubMedCrossRefGoogle Scholar
  62. 62.
    Wagner AM, Jorba O, Bonet R, Ordonez-Llanos J, Perez A. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2003 Jul;88(7):3212–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Lins RL, Matthys KE, Billiouw JM, Dratwa M, Dupont P, Lameire NH, Peeters PC, Stolear JC, Tielemans C, Maes B, Verpooten GA, Ducobu J, Carpentier YA. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol 2004 Oct;62(4):287–94.PubMedGoogle Scholar
  64. 64.
    Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. Int J Cardiol 2005;104:338–45.PubMedCrossRefGoogle Scholar
  65. 65.
    Empen K, Geiss HC, Lehrke M, Otto C, Schwandt P, Parhofer KG. Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia. Nutr Metab Cardiovasc Dis 2003 Apr;13(2):87–92.PubMedCrossRefGoogle Scholar
  66. 66.
    Ikejiri A, Hirano T, Murayama S, Yoshino G, Gushiken N, Hyodo T, Taira T, Adachi M. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 2004 Sep;53(9):1113–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, Poledne R, Stavek P, Ceska R. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002 Oct;144(4):E6.PubMedGoogle Scholar
  68. 68.
    Manuel-Y-Keenoy B, Van Campenhout C, Vertommen J, De Leeuw I. Effects of Atorvastatin on LDL sub-fractions and peroxidation in type 1 diabetic patients: a randomised double-blind placebo-controlled study. Diabetes Metab Res Rev 2003 Nov–Dec;19(6):478–86.PubMedCrossRefGoogle Scholar
  69. 69.
    McKenney JM, McCormic LS, Schaefer EJ et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001;88:270–4.PubMedCrossRefGoogle Scholar
  70. 70.
    O'Keefe JH Jr, Captain BK, Jones PG, Harris WS. Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern. Prev Cardiol 2004;7(4):154–60.PubMedGoogle Scholar
  71. 71.
    Le N-A, Innis-Whitehouse W, Li X et al. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 2000;49:167–77.PubMedCrossRefGoogle Scholar
  72. 72.
    Lemieux I, Salomon H, Despres JP. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients. Ann Med 2003;35(6):442–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004 Apr 8;350(15):1505–15.PubMedCrossRefGoogle Scholar
  74. 74.
    Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 2001;87(1):44–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Geiss HC, Otto C, Schwandt P, Parhofer KG. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism 2001;50(8):983–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Tsimihodimos V, Karabina SA, Tambaki A, Bairaktari E, Achimastos A, Tselepis A, Elisaf M. Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB. J Cardiovasc Pharmacol 2003;42(2):304–10.PubMedCrossRefGoogle Scholar
  77. 77.
    Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, Fuller JH, Julier K, Mackness MI, Neil HA; CARDS Investigators. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 2003;167:243–55.PubMedCrossRefGoogle Scholar
  78. 78.
    van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003;16:238–44.PubMedCrossRefGoogle Scholar
  79. 79.
    Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL, Pieper JA. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy 2005;25:335–44.PubMedCrossRefGoogle Scholar
  80. 80.
    Caslake MJ, Stewart G, Day SP, Daly E, McTaggart F, Chapman MJ, Durrington P, Laggner P, Mackness M, Pears J, Packard CJ. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 2003;171(2):245–53.PubMedCrossRefGoogle Scholar
  81. 81.
    Davidson MH, Toth PP. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 2004;73–104.Google Scholar
  82. 82.
    Rizzo M, Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment. QJM—Int J Med 2006;99:1–14.Google Scholar
  83. 83.
    Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004;6:381–7.PubMedGoogle Scholar
  84. 84.
    Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453–62.PubMedGoogle Scholar
  85. 85.
    Otvos J, Cronwell W, Shalaurova I. LDL particle but not LDL cholesterol are highly elevated in the metabolic syndrome. Results from the Framingham Offspring Study. Circulation 2003;108:IV-740. (abstract)Google Scholar
  86. 86.
    Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002;106:1930–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002;22:1175–80.PubMedCrossRefGoogle Scholar
  88. 88.
    Otvos JD, Freedman DS, Pegus C. LDL and HDl particle subclasses are independent predictors of cardiovascular events in Veteran Affairs HDL Intervention Trial (VA-HIT). Paper presented at the AHA Annual Scientific Session. Chicago, USA, 2002.Google Scholar
  89. 89.
    Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999;25:199–211.PubMedGoogle Scholar
  90. 90.
    Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996;94:2146–53.PubMedGoogle Scholar
  91. 91.
    Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999;99:1959–64.PubMedGoogle Scholar
  92. 92.
    Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996;16:697–704.PubMedGoogle Scholar
  93. 93.
    Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227–39.PubMedCrossRefGoogle Scholar
  94. 94.
    Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046–51.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2006

Authors and Affiliations

  1. 1.Dipartimento di Medicina Clinica e delle Patologie EmergentiUniversita’ di PalermoPalermoItaly
  2. 2.Department of Internal Medicine, Division of Endocrinology and DiabetologyUniversity Hospital ZurichZurichSwitzerland

Personalised recommendations